• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Incyte Corporation - Articles and news items


First patient treated in the Phase III ECHO-301 study

Industry news / 23 June 2016 / Victoria White, Digital Content Producer

ECHO-301 will evaluate Incyte’s epacadostat with Merck’s pembrolizumab as first-line treatment for patients with advanced or metastatic melanoma…


Phase I/II trial of INCAGN1876 in solid tumours starts

Industry news / 22 June 2016 / Victoria White, Digital Content Producer

The open-label, dose-escalation portion of the trial will evaluate the safety and tolerability of INCAGN1876 in patients with solid tumours…


New data for baricitinib in rheumatoid arthritis presented at EULAR

Industry news / 9 June 2016 / Victoria White, Digital Content Producer

Findings from the RA-BEYOND study demonstrate that baricitinib was superior to placebo at inhibiting progressive radiographic joint damage…


Incyte to acquire ARIAD’s European operations for $140m

Industry news / 9 May 2016 / Victoria White, Digital Content Producer

The companies will also enter into a license agreement whereby Incyte will obtain an exclusive license to develop and commercialise Iclusig…

acr 20 response

Lilly and Incyte announce results from RA-BEACON baricitinib study

Industry news / 31 March 2016 / Victoria White

The study, in patients with rheumatoid arthritis, met its primary endpoint of improved ACR 20 response for baricitinib compared with placebo…


Incyte discontinues JANUS 1 study of ruxolitinib plus capecitabine

Industry news / 11 February 2016 / Victoria White

Incyte has explained that its decision to stop the study was made after a planned interim analysis of JANUS 1 demonstrated that ruxolitinib plus capecitabine did not show a sufficient level of efficacy to warrant continuation.


Lilly and Incyte submit NDA for baricitinib to the FDA

Industry news / 19 January 2016 / Victoria White

The new drug application (NDA) has been submitted for the approval of oral once-daily baricitinib for the treatment of moderately-to-severely active rheumatoid arthritis…

incyte and astrazeneca

Incyte and AstraZeneca announce new lung cancer trial collaboration

Industry news / 11 January 2016 / Victoria White

Incyte and AstraZeneca are to evaluate the efficacy and safety of Incyte’s INCB39110 in combination with AstraZeneca’s Tagrisso (osimertinib) as a second-line treatment for patients with EGFR mutation-positive non-small cell lung cancer…


Baricitinib demonstrates superiority to adalimumab in rheumatoid arthritis

Industry news / 10 November 2015 / Victoria White

Baricitinib demonstrated superiority over adalimumab (Humira) after 12 weeks based on several critical measures of rheumatoid arthritis disease activity…


Baricitinib demonstrates superiority to adalimumab in rheumatoid arthritis

Industry news / 14 October 2015 / Victoria White

Baricitinib is a once-daily, oral, selective JAK1 and JAK2 inhibitor for patients with moderately-to-severely active rheumatoid arthritis…


Incyte and Merck to investigate epacadostat and Keytruda in melanoma

Industry news / 13 October 2015 / Victoria White

Preclinical evidence suggests that the combination of these two agents may lead to an enhanced anti-tumour immune response…


Baricitinib superior to methotrexate in rheumatoid arthritis

Industry news / 29 September 2015 / Victoria White

In a Phase II study in moderately-to-severely active rheumatoid arthritis, baricitinib was superior to methotrexate based on ACR20 response…


Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +